Trial · NCT03964415
Adverse events302
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 302
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 51 | 1,942 | 60 |
| other | Diarrhoea | Gastrointestinal disorders | Group 2: Placebo | 54 | 1,945 | 61 |
| other | Nausea (Solicited) | Gastrointestinal disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 520 | 1,942 | 758 |
| other | Nausea (Solicited) | Gastrointestinal disorders | Group 2: Placebo | 361 | 1,945 | 552 |
| other | Vomiting (Solicited) | Gastrointestinal disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 128 | 1,942 | 154 |
| other | Vomiting (Solicited) | Gastrointestinal disorders | Group 2: Placebo | 85 | 1,945 | 115 |
| other | Chills (Solicited) | General disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 857 | 1,942 | 1,405 |
| other | Chills (Solicited) | General disorders | Group 2: Placebo | 342 | 1,945 | 533 |
| other | Fatigue (Solicited) | General disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 1,323 | 1,942 | 3,376 |
| other | Fatigue (Solicited) | General disorders | Group 2: Placebo | 928 | 1,945 | 2,018 |
| other | Pyrexia (Solicited) | General disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 400 | 1,942 | 508 |
| other | Pyrexia (Solicited) | General disorders | Group 2: Placebo | 137 | 1,945 | 174 |
| other | Vaccination Site Erythema (Solicited) | General disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 47 | 1,942 | 66 |
| other | Vaccination Site Erythema (Solicited) | General disorders | Group 2: Placebo | 7 | 1,945 | 7 |
| other | Vaccination Site Pain (Solicited) | General disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 1,519 | 1,942 | 5,543 |
| other | Vaccination Site Pain (Solicited) | General disorders | Group 2: Placebo | 695 | 1,945 | 1,521 |
| other | Vaccination Site Swelling (Solicited) | General disorders | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 89 | 1,942 | 144 |
| other | Vaccination Site Swelling (Solicited) | General disorders | Group 2: Placebo | 9 | 1,945 | 10 |
| other | Anal Chlamydia Infection | Infections and infestations | Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 | 22 | 1,942 | 22 |
| other | Anal Chlamydia Infection | Infections and infestations | Group 2: Placebo | 39 | 1,945 | 39 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03964415/events